Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Current Deferred Revenue (2017 - 2021)

Catheter Precision has reported Current Deferred Revenue over the past 5 years, most recently at $1.8 million for Q2 2021.

  • Quarterly Current Deferred Revenue fell 3.87% to $1.8 million in Q2 2021 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Jun 2021, down 3.87% year-over-year, with the annual reading at $2.5 million for FY2020, 24.24% down from the prior year.
  • Current Deferred Revenue was $1.8 million for Q2 2021 at Catheter Precision, up from $1.8 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $3.3 million in Q4 2019 and troughed at $1.7 million in Q4 2017.
  • The 5-year median for Current Deferred Revenue is $1.9 million (2020), against an average of $2.0 million.
  • Year-over-year, Current Deferred Revenue soared 91.53% in 2019 and then dropped 24.24% in 2020.
  • A 5-year view of Current Deferred Revenue shows it stood at $1.7 million in 2017, then grew by 0.53% to $1.7 million in 2018, then soared by 91.53% to $3.3 million in 2019, then dropped by 24.24% to $2.5 million in 2020, then decreased by 28.52% to $1.8 million in 2021.
  • Per Business Quant, the three most recent readings for VTAK's Current Deferred Revenue are $1.8 million (Q2 2021), $1.8 million (Q1 2021), and $2.5 million (Q4 2020).